BLOOD PRESSURE VARIABILITY AS A FACTOR OF BETTER CARDIOPROTECTIVE EFFICACY OF RENAL DENERVATION-Reference-Cited by-同舟云学术

BLOOD PRESSURE VARIABILITY AS A FACTOR OF BETTER CARDIOPROTECTIVE EFFICACY OF RENAL DENERVATION

Published:2018-07-14 Issue:2 Volume:33 Page:9-15
ISSN:2073-8552
Container-title:Siberian Medical Journal
language:
Short-container-title:Sib. med. ž. (Tomsk)

Author:

Sitkova E. S.,Mordovin V. F.,Pekarskii S. E.,Ripp T. M.,Falkovskaya A. Yu.,Ryabova T. R.,Mochula O. V.,Usov V. Yu.

Publisher

Cardiology Research Institute

Reference13 articles.

1. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., Christiaens T., Cifkova R., De Barker G., Dominiczak A., Galderisi M., Grobbee D. E., Jaarsma T., Kirchhof P., Kjeldsen S. E., Laurent S., Manolis A. J., Nilsson P. M., Ruilope L. M., Schmieder R. E., Sirnes P. A., Sleight P., Viiqimaa M., Waeber B., Zannad F. Task Force Members. Guidelines 2013 ESH/ESC for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertension. 2013; 31(7): 1281–1357. DOI: 10.1097/01. hjh.0000431740.32696.cc.

2. Rothwell M., Howard C., Dolan E., O’Brien E., Dobson J., Dahlöf B., Sever P., Poulter N. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375(9718): 895–905. https://doi.org/10.1016/j.hjc.2017.12.016.

3. Aalbers J. Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk. Cardiovasc. J. Afr. 2010; 21(2): 115–116.

4. De Jager R. L., Sanders M. F., Bots M. L., Lobo M. D., Ewen S., Beeftink M. M., Böhm M., Daemen J., Dörr O., Hering D., Mahfoud F., Nef H., Ott C., Saxena M., Schmieder R. E., Schlaich M. P., Spiering W., Tonino P. A., Verloop W. L., Vink E. E., Vonken E. J., Voskuil M., Worthley S. G., Blankestijn P. J. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin. Res. Cardiol. 2016; 105(9): 755–762. DOI: 10.1007/s00392-016-0984-y.

5. Böhm M., Mahfoud F., Ukena C., Hoppe U. C., Narkiewicz K., Negoita M., Ruilope L., Schlaich M. P., Schmieder R. E., Whitbourn R., Williams B., Zeymer U., Zirlik A., Mancia G.; GSR Investigators. First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients with Uncontrolled Hypertension. Hypertension. 2015; 65(4): 766–774. DOI: 10.1161/HYPERTENSIONAHA.114.05010.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. МРТ-фенотипы повреждения головного мозга у больных резистентной артериальной гипертензией и возможности их коррекции после ренальной денервации;Ateroscleroz;2023-10-06

2. MRI-phenotype of kidney structural changes in patients with resistant hypertension: correlations with functional markers;Nephrology (Saint-Petersburg);2023-09-12

3. Distal renal denervation: cardioprotection in patients with resistant hypertension;Cardiovascular Therapy and Prevention;2020-09-05

4. Machine Learning Methods in Assessing the Risks of Target Organ Damage in Masked Hypertension;Kardiologiia;2020-05-04

5. Cardiac pathology in patients with resistant hypertension;The Siberian Medical Journal;2019-11-04